Curaleaf (CURA) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenue was $331 million, down 1% year-over-year, with international growth offsetting declines in key U.S. states and adjusted gross margin up 312 basis points to 49%.

• Adjusted EBITDA was $75 million (23% margin), consistent with last year.

• Strategic focus shifted to margin refinement, organic growth, cash flow optimization, and disciplined expansion.

• International segment, especially Germany and the UK, showed strong growth, with international revenue up 82% year-over-year and 17% sequentially to $30 million.

• Management is executing a "Return to Our Roots" program, emphasizing operational efficiency and portfolio rationalization.

Financial highlights

• Q3 revenue: $331 million, down 1% year-over-year; gross profit: $160.5 million; gross margin: 49%.

• Adjusted gross profit: $161 million; adjusted gross margin: 49%.

• Adjusted EBITDA: $75 million, flat year-over-year; margin up 20 basis points to 23%.

• Net loss from continuing operations: $44 million; net loss per share: $0.07.

• Operating cash flow YTD: $119 million; free cash flow YTD: $53 million.

Outlook and guidance

• Q4 revenue expected to be flat to up 1% sequentially; Adjusted EBITDA margin to remain consistent with Q3.

• Full-year operating cash flow anticipated to exceed $135 million.

• International business projected to surpass $100 million in annual revenue.

• Focus on sustainable, profitable organic growth and maintaining share in challenged markets.

• Strategic emphasis on international expansion and diversification to mitigate concentration risk.